Roth MKM Reiterates Buy on Bio-Path Hldgs, Maintains $20 Price Target
$BPTH
Biotechnology: Pharmaceutical Preparations
Health Care
Roth MKM analyst Philip Shen reiterates Bio-Path Hldgs (NASDAQ:BPTH) with a Buy and maintains $20 price target.
Save time and jump to the most important pieces.
SC 13G/A - BIO-PATH HOLDINGS, INC. (0001133818) (Subject)
SC 13G/A - BIO-PATH HOLDINGS, INC. (0001133818) (Subject)
SC 13G - BIO-PATH HOLDINGS INC (0001133818) (Subject)
4 - BIO-PATH HOLDINGS, INC. (0001133818) (Issuer)
4 - BIO-PATH HOLDINGS, INC. (0001133818) (Issuer)
4 - BIO-PATH HOLDINGS, INC. (0001133818) (Issuer)
Expands DNAbilize® Technology Beyond Oncology into Obesity Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the third quarter ended September 30, 2024 and provided an update on recent corporate developments. "The third quarter was a particularly productive period for Bio-Path as we initiated our obesity program, which marks the first application of our DNAbilize® platform beyond oncology and highlights i
HOUSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, November 15, 2024 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2024 and to provide a business overview. To access the live conference call, please call (844) 481-3014 (domestic) or (412) 317-1879 (international) at least five minutes prior to the start time. A live audio webcast of the call will also be available on the P
HOUSTON, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the second quarter ended June 30, 2024 and provided an update on recent corporate developments. "The first half of 2024 was marked by considerable corporate and clinical progress across the organization. We were encouraged by the bolus of data we presented at ASCO and EHA as they underscore the potential of a prexigebersen combination regimen as a safe and effective treatment for some of the most vulnerabl
HOUSTON, April 06, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the appointment of Aline Sherwood to its Board of Directors on March 31, 2022. Ms. Sherwood replaced Martina Molsbergen, who stepped down from the Board of Directors on February 14, 2022. "We are delighted to welcome Aline to the Bio-Path Board of Directors. With her extensive background in biotechnology communications, Aline synthesizes complex science into compelling messaging, which is instrumental in guiding our communications
Roth Capital initiated coverage of Bio-Path with a rating of Buy
ROTH Capital initiated coverage of Bio-Path with a rating of Buy and set a new price target of $13.00
Expands DNAbilize® Technology Beyond Oncology into Obesity Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the third quarter ended September 30, 2024 and provided an update on recent corporate developments. "The third quarter was a particularly productive period for Bio-Path as we initiated our obesity program, which marks the first application of our DNAbilize® platform beyond oncology and highlights i
HOUSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, November 15, 2024 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2024 and to provide a business overview. To access the live conference call, please call (844) 481-3014 (domestic) or (412) 317-1879 (international) at least five minutes prior to the start time. A live audio webcast of the call will also be available on the P
HOUSTON, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ:BPTH) ("Bio-Path" or the "Company"), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it has closed its previously announced private placement priced at-the-market under Nasdaq rules for the issuance and sale of an aggregate of 4,597,702 shares of its common stock (or common stock equivalents in lieu thereof), series A warrants to purchase up to 6,407,657 shares of common stock and short-term series B warrants to purchase up to 6,407,657 shares of common stock at a purchase pric
8-K - BIO-PATH HOLDINGS, INC. (0001133818) (Filer)
10-Q - BIO-PATH HOLDINGS, INC. (0001133818) (Filer)
DEFA14A - BIO-PATH HOLDINGS, INC. (0001133818) (Filer)
Roth MKM analyst Philip Shen reiterates Bio-Path Hldgs (NASDAQ:BPTH) with a Buy and maintains $20 price target.
Peter H. Nielsen, President and Chief Executive Officer of Bio-Path, said, "With the increased clinical data that we have generated, we are now able to develop the biomarkers needed to incorporate into our oncology studies. In addition, we have completed preparations for preclinical work to support advancing prexigebersen as a potential treatment for obesity. In tandem, we are designing development plans for first-in-human clinical studies in this expansive global market for weight loss."
Bio-Path Holdings, Inc. (NASDAQ:BPTH) shares are trading higher Friday after the company announced interim results from its Phase 2 study of prexigebersen in combination with decitabine and venetoclax for the treatment of acute myeloid leukemia. The Details: Bio-Path said the data presented showed prexigebersen continues to be well-tolerated and demonstrated efficacy results in two reporting cohorts including evaluable newly diagnosed AML patients and evaluable refractory/relapsed AML patients, both of which exceeded outcomes with frontline therapy. “It was a pleasure to present these compelling data to an audience of European oncologists who treat AML patients and understand the co